N
RVMD icon

Natixis’s Revolution Medicines RVMD Stock Holding History

Natixis’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.59M Buy
8,467
+3,722
+78% +$544K 0.01% 672
2026
Q1 		$461K Sell
4,745
-7,714
-62% -$779K ﹤0.01% 823
2025
Q4 		$992K Buy
+12,459
New +$817K ﹤0.01% 722
2025
Q1 		– Sell
-1,170
Closed -$51.2K – 1163
2024
Q4 		$51.2K Sell
1,170
-83,624
-99% -$4.22M ﹤0.01% 881
2024
Q3 		$3.85M Buy
84,794
+83,325
+5,672% +$3.63M 0.02% 348
2024
Q2 		$57K Sell
1,469
-4,606
-76% -$172K ﹤0.01% 779
2024
Q1 		$196K Buy
+6,075
New +$180K ﹤0.01% 718
2022
Q1 		– Sell
-13,200
Closed -$332K – 1309
2021
Q4 		$332K Buy
+13,200
New +$372K ﹤0.01% 1114

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Natixis's RVMD Position: Q2 2026 in Review

Natixis increased its Revolution Medicines (RVMD) stake by 78% in Q2 2026, buying an estimated $544K and bringing the position to 8,467 shares worth $1.59M. The position accounts for 0.01% of the portfolio, ranked #672.

Natixis first reported a position in RVMD in Q4 2021 and has held it in 8 quarters since. The position peaked at $3.85M in Q3 2024. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Natixis held 8,467 shares of Revolution Medicines worth $1.59M as of Q2 2026.
  • Natixis bought 3,722 Revolution Medicines shares in Q2 2026, an estimated $544K.
  • Revolution Medicines made up 0.01% of Natixis's portfolio in Q2 2026, its #672 holding.
  • Natixis first reported a position in Revolution Medicines in Q4 2021 and has held it in 8 quarters since.
  • Natixis's Revolution Medicines position peaked at $3.85M in Q3 2024.
  • 690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.